Rehab Alnabhan1, Alejandro Madrigal1, Aurore Saudemont2. 1. University College London, Cancer Institute, Royal Free Campus, London, United Kingdom; Anthony Nolan Research Institute, Royal Free Campus, London, United Kingdom. 2. University College London, Cancer Institute, Royal Free Campus, London, United Kingdom; Anthony Nolan Research Institute, Royal Free Campus, London, United Kingdom. Electronic address: aurore.saudemont@anthonynolan.org.
Abstract
BACKGROUND AIMS: Natural killer (NK) cells play important roles in the clearance of infection and transformed cells. Cord blood (CB) is currently used as a source of hematopoietic stem cells for transplantation and is a potential source of NK cells for immunotherapy. We previously showed that CB NK cells are immature and less cytotoxic as compared with peripheral blood (PB) NK cells. We aimed to identify which cytokines, among interleukin (IL)-2, IL-12, IL-15 and IL-18 and their combinations, could fully activate CB NK cells as compared with PB NK cells. METHODS: We performed a comprehensive analysis of phenotype and functionality of cytokine-activated NK cells. RESULTS: Our results show that the lower responsiveness of CB NK cells to IL-2 is associated with lower levels of expression of IL-2 receptors and decreased phosphorylation of STAT5 as compared with PB NK cells. Activation of CB NK cells with IL-15+18 led to the most robust proliferative response and higher interferon-γ and tumor necrosis factor-α secretion, whereas activation with IL-15+2 promoted enhanced cytotoxicity. PB NK cells responded significantly better to IL-2 than to CB NK cells but were also fully activated with other cytokine treatments including IL-15, IL-15+2 or IL-15+18. It was also possible to use cytokines to generate memory-like NK cells, with sustained ability to produce interferon-γ, from both CB and PB. CONCLUSIONS: CB NK cells are fully functional on activation with IL-15+2 or IL-15+18 rather than IL-2 alone as observed for PB NK cells. These cytokines should be considered in the future to activate CB NK cells for therapeutic purposes.
BACKGROUND AIMS: Natural killer (NK) cells play important roles in the clearance of infection and transformed cells. Cord blood (CB) is currently used as a source of hematopoietic stem cells for transplantation and is a potential source of NK cells for immunotherapy. We previously showed that CB NK cells are immature and less cytotoxic as compared with peripheral blood (PB) NK cells. We aimed to identify which cytokines, among interleukin (IL)-2, IL-12, IL-15 and IL-18 and their combinations, could fully activate CB NK cells as compared with PB NK cells. METHODS: We performed a comprehensive analysis of phenotype and functionality of cytokine-activated NK cells. RESULTS: Our results show that the lower responsiveness of CB NK cells to IL-2 is associated with lower levels of expression of IL-2 receptors and decreased phosphorylation of STAT5 as compared with PB NK cells. Activation of CB NK cells with IL-15+18 led to the most robust proliferative response and higher interferon-γ and tumor necrosis factor-α secretion, whereas activation with IL-15+2 promoted enhanced cytotoxicity. PB NK cells responded significantly better to IL-2 than to CB NK cells but were also fully activated with other cytokine treatments including IL-15, IL-15+2 or IL-15+18. It was also possible to use cytokines to generate memory-like NK cells, with sustained ability to produce interferon-γ, from both CB and PB. CONCLUSIONS: CB NK cells are fully functional on activation with IL-15+2 or IL-15+18 rather than IL-2 alone as observed for PB NK cells. These cytokines should be considered in the future to activate CB NK cells for therapeutic purposes.
Authors: Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz Journal: Transplant Cell Ther Date: 2020-09-29
Authors: Ismael Samudio; Katayoun Rezvani; Hila Shaim; Elyse Hofs; Mor Ngom; Luke Bu; Guoyu Liu; Jason T C Lee; Suzan Imren; Vivian Lam; Grace F T Poon; Maryam Ghaedi; Fumio Takei; Keith Humphries; William Jia; Gerald Krystal Journal: Blood Date: 2016-03-03 Impact factor: 22.113
Authors: Dara M Strauss-Albee; Emily C Liang; Thanmayi Ranganath; Natali Aziz; Catherine A Blish Journal: Cytometry B Clin Cytom Date: 2016-11-08 Impact factor: 3.058
Authors: Anne M Dickinson; Jean Norden; Shuang Li; Ilona Hromadnikova; Christoph Schmid; Helga Schmetzer; Hans Jochem-Kolb Journal: Front Immunol Date: 2017-06-07 Impact factor: 7.561
Authors: Moriah J Castleman; Stephanie M Dillon; Tezha A Thompson; Mario L Santiago; Martin D McCarter; Edward Barker; Cara C Wilson Journal: J Immunol Date: 2021-06-11 Impact factor: 5.426